CEO Joaquin Duato said the spinout will help the healthcare giant focus on medtech areas with higher growth and margins, such ...
While no patients have been harmed, the FDA categorized the action as a Class I recall because of the potential for serious ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback